{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:51:38Z","timestamp":1777395098768,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40261-022-01226-7","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T09:03:05Z","timestamp":1671008585000},"page":"61-74","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CHAnges in Diuretic Medication Prescribing and Surrogate Laboratory Parameters After Initiating EmpagliflOziN in Veterans (CHAMPION Cohort Study)"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-3463","authenticated-orcid":false,"given":"Tanvi","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Halsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alamdeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Minchak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Hobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davida","family":"Eppes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","volume":"75","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33\u201359.","journal-title":"Drugs"},{"key":"1226_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","volume":"58","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429\u201342.","journal-title":"Diabetologia"},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"1226_CR4","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1097\/HJH.0000000000000719","volume":"33","author":"KP Imprialos","year":"2015","unstructured":"Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens. 2015;33:2185\u201397.","journal-title":"J Hypertens"},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2016;4:211\u201320.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1226_CR6","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180\u201393.","journal-title":"Diabetes Obes Metab"},{"key":"1226_CR7","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","volume":"15","author":"HJ Lambers Heerspink","year":"2013","unstructured":"Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.1016\/j.ijcard.2013.07.241","volume":"168","author":"J Oh","year":"2013","unstructured":"Oh J, Kang SM, Hong N, Youn JC, Han S, Jeon ES, et al. Hemoconcen- tration is a good prognostic predictor for clinical outcomes in acute heart failure: data from the Korean Heart Failure (KorHF) Registry. Int J Cardiol. 2013;168:4739\u201343.","journal-title":"Int J Cardiol"},{"key":"1226_CR9","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","volume":"59","author":"N Sattar","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333\u20139. https:\/\/doi.org\/10.1007\/s00125-016-3956-x.","journal-title":"Diabetologia"},{"key":"1226_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018097","volume":"7","author":"IR Mordi","year":"2017","unstructured":"Mordi IR, Singh JS, Baig F, Choy AM, McCrimmon RJ, Struthers AD, et al. Renal and cardiovascular effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop diuretics in diabetic patients with chronic heart failure (RECEDE-CHF): protocol for a randomized controlled double-blind cross-over trial. BMJ Open. 2017;7: e018097. https:\/\/doi.org\/10.1136\/bmjopen-2017-018097.","journal-title":"BMJ Open"},{"key":"1226_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","volume":"13","author":"DA Sica","year":"2011","unstructured":"Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens. 2011;13:639\u201343.","journal-title":"J Clin Hypertens"},{"issue":"6","key":"1226_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","volume":"31","author":"WP Glasheen","year":"2017","unstructured":"Glasheen WP, Renda A, Dong Y. Diabetes Complications Severity Index (DCSI)-update and ICD-10 translation. J Diabetes Complic. 2017;31(6):1007\u201313. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.02.018.","journal-title":"J Diabetes Complic"},{"key":"1226_CR13","unstructured":"AHRQ quality indicators: guide to prevention quality indicators: hospital admission for ambulatory care sensitive conditions. AHRQ Pub. No. 02-R0203. Rockville: Agency for Healthcare Research and Quality; 2001."},{"issue":"4","key":"1226_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/MLR.0b013e31827da95a","volume":"51","author":"L Wang","year":"2013","unstructured":"Wang L, Porter B, Maynard C, et al. Predicting risk of hospitalization or death among patients receiving primary care in the Veterans Health Administration. Med Care. 2013;51(4):368\u201373.","journal-title":"Med Care"},{"issue":"4","key":"1226_CR15","first-page":"188","volume":"12","author":"WP Glasheen","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 update and ICD-10 translation. Am Health Drug Benefits. 2019;12(4):188\u201397.","journal-title":"Am Health Drug Benefits."},{"issue":"11","key":"1226_CR16","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/jcmm.13205","volume":"21","author":"W Liang","year":"2017","unstructured":"Liang W, Ma H, Cao L, Yan W, Yang J. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med. 2017;21(11):2634\u201342.","journal-title":"J Cell Mol Med"},{"key":"1226_CR17","unstructured":"Kanderi T, Vaitla P. Torsemide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559175\/"},{"key":"1226_CR18","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","volume":"142","author":"AM Jackson","year":"2020","unstructured":"Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation. 2020;142:1040\u201354.","journal-title":"Circulation"},{"key":"1226_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"JF List","year":"2009","unstructured":"List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650\u20137. https:\/\/doi.org\/10.2337\/dc08-1863.","journal-title":"Diabetes Care"},{"key":"1226_CR20","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1111\/dom.12322","volume":"16","author":"S Sha","year":"2014","unstructured":"Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-M\u00f6rschel L. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087\u201395. https:\/\/doi.org\/10.1111\/dom.12322.","journal-title":"Diabetes Obes Metab"},{"key":"1226_CR21","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","volume":"139","author":"M Sano","year":"2019","unstructured":"Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019;139:1985\u20137.","journal-title":"Circulation"},{"key":"1226_CR22","doi-asserted-by":"publisher","first-page":"22396","DOI":"10.1038\/s41598-020-78734-z","volume":"10","author":"J Aberle","year":"2020","unstructured":"Aberle J, Menzen M, Schmid SM, et al. Dapagliflozin effects on hematocrit, red blood cell count, and reticulocytes in insulin-treated patients with type 2 diabetes. Sci Rep. 2020;10:22396.","journal-title":"Sci Rep"},{"key":"1226_CR23","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","volume":"141","author":"CD Mazer","year":"2020","unstructured":"Mazer CD, Hare GMT, Connelly PW, et al. Effects of empagliflozin on erythromycin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2020;141:704\u20137.","journal-title":"Circulation"},{"issue":"10","key":"1226_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1253\/circrep.CR-20-0041","volume":"2","author":"A Shirakabe","year":"2020","unstructured":"Shirakabe A, Matsushita M, Kiuchi K, Okazaki H, Inami T, Takayasu T, et al. Empagliflozin administration can decrease the dose of loop diuretics and prevent the exacerbation of renal tubular injury in patients with compensated heart failure complicated by diabetes. Circ Rep. 2020;2(10):565\u201375. https:\/\/doi.org\/10.1253\/circrep.CR-20-0041.","journal-title":"Circ Rep."},{"issue":"16","key":"1226_CR25","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","volume":"144","author":"M Packer","year":"2021","unstructured":"Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021;144(16):1284\u201394. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056824.","journal-title":"Circulation"},{"key":"1226_CR26","doi-asserted-by":"publisher","first-page":"420","DOI":"10.2337\/dc14-1096","volume":"38","author":"I Tikkanen","year":"2015","unstructured":"Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420\u20138.","journal-title":"Diabetes Care"},{"issue":"12","key":"1226_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1093\/ajh\/hpaa073","volume":"33","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Fitchett D, Ofstad AP. Empagliflozin for patients with presumed resistant hypertension: a post hoc analysis of the EMPA-REG OUTCOME trial. Am J Hypertens. 2020;33(12):1092\u2013101.","journal-title":"Am J Hypertens"},{"issue":"33","key":"1226_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100725","volume":"10","author":"JL Benham","year":"2021","unstructured":"Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc. 2021;10(33): 100725. https:\/\/doi.org\/10.1016\/j.ijcha.2021.100725.","journal-title":"Int J Cardiol Heart Vasc."},{"issue":"3","key":"1226_CR29","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","volume":"99","author":"BJ Kraus","year":"2021","unstructured":"Kraus BJ, Weir MR, Bakris GL, Mattheus M, Cherney DZI, Sattar N, et al. Characterization and implications of the initial estimated glomerular filtration rate \u2018dip\u2019 upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021;99(3):750\u201362. https:\/\/doi.org\/10.1016\/j.kint.2020.10.031.","journal-title":"Kidney Int"},{"issue":"9","key":"1226_CR30","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2215\/CJN.01130121","volume":"16","author":"DZI Cherney","year":"2021","unstructured":"Cherney DZI, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, Frederich R, et al. VERTIS CV Investigators. Ertugliflozin and slope of chronic eGFR: prespecified analyses from the randomized VERTIS CV trial. Clin J Am Soc Nephrol. 2021;16(9):1345\u201354. https:\/\/doi.org\/10.2215\/CJN.01130121.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1226_CR31","doi-asserted-by":"publisher","unstructured":"Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, et al. Effects of canagliflozin in patients with baseline eGFR <30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial. Clin J Am Soc Nephrol. 2020;15(12):1705\u201314. https:\/\/doi.org\/10.2215\/CJN.10140620.","DOI":"10.2215\/CJN.10140620"},{"issue":"7","key":"1226_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.602251","volume":"7","author":"A Ibrahim","year":"2020","unstructured":"Ibrahim A, Ghaleb R, Mansour H, et al. Safety and efficacy of adding dapagliflozin to furosemide in type 2 diabetes patients with decompensated heart failure and reduced ejection fraction. Front Cardiovasc Med. 2020;7(7): 602251.","journal-title":"Front Cardiovasc Med."},{"key":"1226_CR33","volume":"24","author":"A Rahhal","year":"2021","unstructured":"Rahhal A, Najim M, Abusweireh A, et al. A comparative study of safety outcomes of sodium glucose cotransporter-2 inhibitors and loop diuretics among diabetic patients using real-world data. Curr Probl Cardiol. 2021;24: 100995.","journal-title":"Curr Probl Cardiol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01226-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T10:10:23Z","timestamp":1673431823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01226-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01226-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"9 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not receive any special grant or funding from agencies in public, commercial or not-for profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors has any conflict of interest to disclose. The results of this study do not represent the views of the federal government or Veterans Health Administration. Additionally, the study was conducted with the resources and support of the Salem VA Medical Center and Veterans Health Administration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Dr Patil and Dr. Halsey have made substantial contributions to the conception and design of the research project as well as the acquisition, analysis, and interpretation of data as well writing the first and final draft of the manuscript. All authors have contributed by offering review of initial manuscript and offered comments to the previous versions for important intellectual content. The final draft of manuscript was written by Tanvi Patil (Primary author).","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}